Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Discover user friendly crypto investment methods that make investing easy and accessible for everyone.
20,852 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Newmont Mining stock rebounded on Friday as gold prices rallied and investors rotated into safe-haven assets. This gu...
A philanthropy CEO chose a London university path for her daughter, cutting annual college costs by roughly $50,000 v...
The U.S. federal debt surpassed $39 trillion for the first time, signaling a turning point for budgeting and markets....
IonQ is set to release Q1 2026 results after the bell, with investors weighing growth across five acquisitions, a Sky...
A hypothetical Berkshire Hathaway partnership with Aurora Innovation could lift investor sentiment and stock momentum...
Stocks jump worldwide as diplomacy signals momentum, suggesting a gentler risk environment for investors in May 2026.
A timely tribute to Ted Turner and the daring moves that built a media empire. From billboard prince to cable mogul, ...
As Innodata prepares to unveil its Q1 2026 results, investors want clarity on growth drivers, margins, and the path t...
Datadog stock climbs after upbeat Q1 results and fresh price targets near $225, underscoring a broader shift to AI-dr...
Arm is quietly becoming backbone of AI as it expands from smartphone CPUs into hyperscale data centers and edge devic...
With yields in play and inflation cooling only slowly, a disciplined dividend portfolio that outlasts a 4% rule offer...